EpiCast Report: Human Immunodeficiency Virus (HIV) – Epidemiology Forecast to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Human immunodeficiency virus (HIV) is a lentivirus that impairs and destructs the CD4 cells of the immune system. This weakens the immune system, leaving an infected individual more susceptible to other illnesses and, over time, impairing the individual's ability to fight off infections.

GlobalData epidemiologists utilized national and international HIV and AIDS databases, surveillance data, and robust peer-reviews journal articles to build the forecast of total prevalent and diagnosed prevalent cases of HIV in the 8MM. HIV is defined as an infection with HIV, regardless of the stage of disease. This corresponds to the International Classification of Diseases 10th edition (ICD-10) code B20. Diagnosed prevalent cases of HIV were segmented by age and sex using country-specific data, whenever available; when data were not available, appropriate proxies were used. For Japan, GlobalData epidemiologists provided an alternative forecast for the 20-year diagnosed prevalent cases of HIV, which better aligns with the ART market sales data after consolidation. GlobalData epidemiologists also provide an alternative forecast for Japan in the EpiCast model based on the reported prevalent HIV cases.

GlobalData epidemiologists forecast that the total prevalent cases of HIV in the 8MM will increase from 3,632,410 in 2015 to 4,266,548 in 2025 at an Annual Growth Rate (AGR) of 1.75%. The US will have the highest number of total prevalent cases of HIV in both 2015 and 2025 at 1,315,263 and 1,514,925, respectively. GlobalData epidemiologists forecast that the diagnosed prevalent cases of HIV in the 8MM will increase from 2,926,335 in 2015 to 3,616,811 in 2025 at an AGR of 2.36%. In Japan, GlobalData epidemiologists forecast the 20-year diagnosed prevalent cases of HIV to increase from 20,438 in 2015 to 25,417 in 2025 at an AGR of 2.44%.

Scope

The Humman Immunodeficiency Virus (HIV) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends for HIV in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China). For the 8MM (US, France, Germany, Italy, Spain, UK, Brazil, and China) it also includes a 10-year epidemiological forecast for the total prevalent cases of HIV (both sexes and all ages), and diagnosed prevalent cases of HIV segmented by sex and age from 2015–2025. The diagnosed prevalent cases of HIV are further segmented into those receiving antiretroviral therapy (ART), those with hepatitis B virus (HBV) co-infection, and those with hepatitis C virus (HCV) co-infection. For Japan, GlobalData epidemiologists provide a 10-year forecast for the 20-year diagnosed prevalent cases of HIV segmented by sex and age from 2015–2025. The 20-year diagnosed prevalent cases of HIV are further segmented into those receiving ART, those with HBV co-infection, and those with HCV co-infection.

The HIV epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.3.1 US

2.3.2 5EU

2.3.3 Japan, Brazil, and China

2.4 Forecast Methodology

2.4.1 Sources Used Tables

2.4.2 Forecast Assumptions and Methods

2.4.3 Sources Not Used

2.5 Epidemiological Forecast for HIV in the 8MM (2015–2025)

2.5.1 Total Prevalent Cases of HIV

2.5.2 Diagnosed Prevalent Cases of HIV

2.5.3 Age-Specific Diagnosed Prevalent Cases of HIV

2.5.4 Sex-Specific Diagnosed Prevalent Cases of HIV

2.5.5 Age-Standardized Diagnosed Prevalent Cases of HIV

2.5.6 Diagnosed Prevalent Cases of HIV Treated with Antiretroviral Therapy

2.5.7 Diagnosed Prevalent Cases of HIV with Hepatitis B Virus Co-infection

2.5.8 Diagnosed Prevalent Cases of HIV with Hepatitis C Virus Co-infection

2.6 Epidemiological Forecast for HIV in Japan (2015–2025)

2.6.1 20-Year Diagnosed Prevalent Cases of HIV

2.6.2 Age-Specific 20-Year Diagnosed Prevalent Cases of HIV

2.6.3 Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV

2.6.4 Age-Standardized 20-Year Diagnosed Prevalent Cases of HIV

2.6.5 Diagnosed 20-Year Prevalent Cases of HIV Treated with Antiretroviral Therapy

2.6.6 Diagnosed 20-Year Prevalent Cases of HIV with Hepatitis B Virus Co-infection

2.6.7 Diagnosed 20-Year Prevalent Cases of HIV with Hepatitis C Virus Co-infection

2.7 Discussion

2.7.1 Epidemiological Forecast Insight

2.7.2 Limitations of the Analysis

2.7.3 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 Physicians and Specialists Included in this Study

3.2.1 Primary Research – Prescriber Survey

3.3 About the Authors

3.3.1 Epidemiologists

3.3.2 Reviewers

3.3.3 Global Director of Therapy Analysis and Epidemiology

3.4 About GlobalData

3.5 About EpiCast

3.6 Disclaimer

Table

Table 1: Risk Factors and Comorbidities for HIV

Table 2: 5EU, Total Prevalence of HIV in Men and Women (%), All Ages, Selected Years, 2001–2015

Table 3: 8MM, Sources of HIV Total Prevalence Data

Table 4: 8MM, Sources of HIV Diagnosed Prevalence Data

Table 5: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan

Table 6: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV on ART

Table 7: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV with HBV Co-infection

Table 8: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV with HCV Co-infection

Table 9: 8MM, Total Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 10: 8MM, Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 11: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, 2015, Cases (N) and Proportions (Row %)

Table 12: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, 2015 (Row %)

Table 13: 8MM, Diagnosed Prevalent HIV Cases Treated with ART, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 14: 8MM, Diagnosed Prevalent HIV Cases with HBV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 15: 8MM, Diagnosed Prevalent HIV Cases with HCV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 16: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 17: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Both Sexes, N, 2015 (Row %)

Table 18: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N, 2015 (Row %)

Table 19: Japan, 20-Year Diagnosed Prevalent HIV Cases Treated with ART, All Ages, Both Sexes 2015–2025, Cases (N) and Proportions (%)

Table 20: Japan, 20-Year Diagnosed Prevalent HIV Cases with HBV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 21: Japan, 20-Year Diagnosed Prevalent HIV Cases with HCV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 22: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Overview of HIV, Men and Women, All Ages, 1990–2015

Figure 2: 8MM, Total Prevalent Cases of HIV, All Ages , Both Sexes, N, Select Years, 2015–2025

Figure 3: 8MM, Diagnosed Prevalent Cases of HIV, All Ages , Both Sexes, N, Select Years, 2015–2025

Figure 4: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, N, Select Years, 2015–2025

Figure 5: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, All Ages, N, Select Years, 2015–2025

Figure 6: 8MM, Age-Standardized Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015

Figure 7: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Figure 8: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015

Frequently asked questions

EpiCast Report: Human Immunodeficiency Virus (HIV) – Epidemiology Forecast to 2025 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Human Immunodeficiency Virus (HIV) – Epidemiology Forecast to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Human Immunodeficiency Virus (HIV) – Epidemiology Forecast to 2025 in real time.

  • Access a live EpiCast Report: Human Immunodeficiency Virus (HIV) – Epidemiology Forecast to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.